A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human
Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I
inhibitor payload, which combine the ability of antibodies to specifically target tumour
cells with the highly potent killing activity of drugs with payloads too toxic for systemic
administration. This is a Phase 1/Phase 2 study to evaluate the effectiveness, safety,
pharmacokinetics (PK) and anti-drug antibody (ADA) of TQB2102 for injection in subjects with
HER2-expressing relapsed/metastatic breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.